Glycotargeting therapeutics

A compound comprising a compound of Formula 1:

• where:
• m is an integer from 1 to 100;
• X is selected from the group consisting of insulin, proinsulin, preproinsulin, glutamic acid decarboxylase-65 (GAD-65), GAD-67, glucose-6 phosphatase 2, insulinoma-associated protein 2, and insulinoma-associated protein 20, myelin basic protein, myelin oligodendrocyte glycoprotein, myelin proteolipid protein, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13;
• Y comprises one or more
• structures represented by one or more of the following Formulae:
• where:
• the left bracket “(” indicates the bond between X and Y;
• the right or bottom bracket and “)” indicates the bond between Y and Z;
• n, where present, is an integer from 1 to 100;
• p, where present, is an integer from 2 to 150;
• q, where present, is an integer from 1 to 44;
• R8, where present, is —CH2— or —CH2—CH2—C(CH3)(CN)—;
• and
• R9, where present, is a direct bond or —C(O)—NH—CH2—CH2—;
• and
• Z comprises one or more liver-targeting moieties.

A composition comprising a compound of Formula 1:

• where:
• m is an integer from 1 to 100;
• X comprises a synthetic self-antigen;
• Y comprises a structure represented by one or more of the following Formulae:
• where:
• the left bracket “(” indicates the bond between X and Y;
• the right or bottom bracket and “)” indicates the bond between Y and Z;
• n is an integer from 1 to 100;
• p is an integer from 2 to 150;
• q is an integer from 1 to 44;
• R8 is —CH2— or —CH2—CH2—C(CH3)(CN)—;
• and
• R9 is a direct bond or —C(O)—NH—CH2—CH2—;
• and
• Z comprises one or more liver-targeting moieties, wherein Z is selected from the group consisting of glucose, glucosamine or N-acetylglucosamine.